[Skip to Content]
[Skip to Content Landing]
Original Investigation
December 2018

Association of the Use of a Mandatory Prescription Drug Monitoring Program With Prescribing Practices for Patients Undergoing Elective Surgery

Author Affiliations
  • 1Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
JAMA Surg. 2018;153(12):1105-1110. doi:10.1001/jamasurg.2018.2666
Key Points

Question  How does mandatory use of a prescription drug monitoring program change the prescribing practices for patients undergoing elective general surgery?

Findings  In this pre-post cohort study of 1057 patients, prescribing practices were compared before and after New Hampshire legislation mandating the use of a prescription drug monitoring program that took effect January 1, 2017. There was no significant change in the rate of opioid prescriptions written or the mean number of pills prescribed.

Meaning  It seems that efforts to curb overprescribing of opioids should be evidence based and should show clinical benefit prior to mandatory implementation, and that patients undergoing elective surgical procedures should be considered differently when developing opioid legislation.

Abstract

Importance  Most states have adopted the routine use of a prescription drug monitoring program (PDMP) to curb overprescribing of opioids. The American College of Surgeons promotes the use of these programs as a “guiding principle to curb the opioid epidemic.” However, there is a paucity of data on the effects of the use of these programs for surgical patient populations.

Objective  To determine the association of the mandatory use of a PDMP with the opioid prescribing practices for patients undergoing general surgery.

Design, Setting, and Participants  A prospective observational cohort study was conducted at an academic hospital in New Hampshire among 1057 patients undergoing representative elective general surgical procedures from July 1, 2016, to June 30, 2017.

Exposures  New state legislation mandated the use of a PDMP and opioid risk-assessment tool for all patients receiving an outpatient opioid prescription in New Hampshire beginning January 1, 2017. The electronic medical prescribing system was modified to facilitate and support compliance with the new requirements.

Main Outcomes and Measures  Change in opioid prescribing practices after January 1, 2017, and time to complete PDMP requirements.

Results  Among the 1057 patients (569 women [53.8%] and 488 men [46.2%]; mean [SD] age, 56.8 [15.4] years), the percentage of patients prescribed opioids after surgery did not decrease significantly (429 of 536 [80.0%] before the new requirements vs 401 of 521 [77.0%] after the requirements; P = .29). The mean number of opioid pills prescribed decreased from 30.8 to 24.0 (22.1%) in the 6 months prior to the mandatory PDMP requirement; the rate of decrease was actually less (from 22.8 to 21.9 pills [3.9%]) in the 6 months after the legislation. These new requirements did not identify any high-risk patients who subsequently were not prescribed opioids. The query and opioid abuse risk calculator together took a median time of 7 minutes (range, 2-17 minutes) to complete.

Conclusions and Relevance  A mandatory PDMP query requirement was not significantly associated with the overall rate of opioid prescribing or the mean number of pills prescribed for patients undergoing general surgical procedures. In no cases was a high-risk patient identified, leading to avoidance of an opioid prescription. A PDMP can be a useful adjunct in certain settings, but this study found that it did not have the intended effect in a population undergoing elective surgical procedures. Legislative efforts to mandate PDMP use should be targeted to populations in which benefit can be demonstrated.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×